Gracell Biotechnologies Reports Updated Clinical Data For FasTCAR-T GC012F For High-Risk, Newly Diagnosed Multiple Myeloma, Demonstrating 100% Stringent Complete Response Rate
Portfolio Pulse from Benzinga Newsdesk
Gracell Biotechnologies (NASDAQ:GRCL) has reported updated clinical data for its FasTCAR-T GC012F treatment for high-risk, newly diagnosed multiple myeloma, demonstrating a 100% stringent complete response rate. The data includes longer-term follow-up from an ongoing Phase 1 trial and three additional patients. The results were presented at the International Myeloma Society Annual Meeting. The data also showed that GC012F was well-tolerated with no new safety signals observed.
September 27, 2023 | 12:33 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Gracell Biotechnologies' FasTCAR-T GC012F treatment for high-risk, newly diagnosed multiple myeloma has shown a 100% stringent complete response rate in a Phase 1 trial. The data also showed that GC012F was well-tolerated with no new safety signals observed.
The positive clinical trial results for Gracell's FasTCAR-T GC012F treatment are likely to boost investor confidence in the company and its product pipeline. This could potentially lead to an increase in the company's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100